CoChat

Rationale and efficacy of interleukin-1 targeting in Erdheim–Chester disease

Aouba, Achille, Georgin-Lavialle, Sophie, Pagnoux, Christian, Martin Silva, Nicolas, Renand, Amédée, Galateau-Salle, Françoise, Le Toquin, Sophie, Bensadoun, Henri, Larousserie, Frederique, Silvera, Stéphane, Provost, Nicole, Candon, Sophie, Seror, Raphaèle, de Menthon, Mathilde, Hermine, Olivier, Guillevin, Loïc, Bienvenu, Boris · 2010 · Blood
Cited by 143

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Erdheim–Chester disease (ECD) pathophysiology remains largely unknown. Its treatment is not codified and usually disappointing. Interferon (IFN)-α therapy lacks efficacy for some life-threatening manifestations and has a poor tolerance profile. Because interleukin (IL)-1Ra synthesis is naturally induced after stimulation by IFN-α, we hypothesized that recombinant IL-1Ra (anakinra) might have some efficacy in ECD. We treated 2 patients who had poor tolerance or contraindication to IFN-α with anakinra as a rescue therapy and measured their serum C-reactive protein, IL-1β, IL-6, and monocytic membranous IL-1α (mIL-1α) levels before, under, and after therapy. Another untreated ECD patient and 5 healthy subjects were enrolled as controls. After treatment, fever and bone pains rapidly disappeared in both patients, as well as eyelid involvement in one patient. In addition, retroperitoneal fibrosis completely or partially regressed, and C-reactive protein, IL-6, and mIL-1α levels decreased to within the normal and control range. Beside injection-site reactions, no adverse event was reported. Therefore, our results support a central role of the IL-1 network, which seemed to be overstimulated in ECD. Its specific blockade using anakinra thereby opens new pathophysiology and therapeutic perspectives in ECD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2010-04-279240

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 143

Metadata

Authors
Aouba, A., Georgin-Lavialle, S., Pagnoux, C., Martin Silva, N., Renand, A., Galateau-Salle, F., Le Toquin, S., Bensadoun, H., Larousserie, F., Silvera, S., Provost, N., Candon, S., Seror, R., de Menthon, M., Hermine, O., Guillevin, L., & Bienvenu, B.
Venue
Blood
Published
2010-11-18
Volume
116
Issue
20
Pages
4070-4076
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W1987596886
Cited by
143
References
5
FWCI
6.09
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rationale and efficacy of interleukin-1 targeting in Erdheim–Chester disease. https://app.cochat.ai/papers/10.1182/blood-2010-04-279240
The paper
Aouba, A., Georgin-Lavialle, S., Pagnoux, C., Martin Silva, N., Renand, A., Galateau-Salle, F., Le Toquin, S., Bensadoun, H., Larousserie, F., Silvera, S., Provost, N., Candon, S., Seror, R., de Menthon, M., Hermine, O., Guillevin, L., & Bienvenu, B. (2010). Rationale and efficacy of interleukin-1 targeting in Erdheim–Chester disease. Blood. https://doi.org/10.1182/blood-2010-04-279240

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.